Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).
- 1 December 1994
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Vol. 14 (12) , 1906-1913
- https://doi.org/10.1161/01.atv.14.12.1906
Abstract
To establish whether lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, exhibits a specific effect on apolipoprotein (apo) A- and apoB-containing lipoproteins, 63 subjects, a subset of the 270 Monitored Atherosclerosis Regression Study (MARS) patients with hypercholesterolemia (190 to 295 mg/dL) and documented coronary artery disease, were randomized into either lovastatin 40 mg twice daily or matching placebo tablets twice daily. Both groups consumed a diet containing 27% calories as fat (polyunsaturated fat/saturated fat ratio, 2.85) and a daily cholesterol intake of less than 250 mg. The plasma lipid and apolipoprotein profiles were determined at the time of randomization and after 2 years of treatment, and the levels of apoA- and apoB-containing lipoprotein families were measured after 2 years of treatment. After this treatment period, the drug group was characterized in comparison with the placebo group by significantly reduced levels of total cholesterol (33%), triglycerides (30%), very-low-density lipoprotein cholesterol (36%), low-density lipoprotein cholesterol (43%), apoB (36%), apoC-III (18%), and apoE (17%) and slightly but insignificantly increased levels of high-density lipoprotein cholesterol (6%) and apoA-I (1%). The 2-year levels of lipoprotein containing apoA-I but no apoA-II (LpA-I) and lipoprotein containing both apoA-I and apoA-II (LpA-I/A-II) particles separated by immunoaffinity chromatography on an anti-apoA-II immunosorber did not differ between the two treatment groups. However, the apoB-containing lipoprotein (Lp) families defined by apolipoprotein composition and separated by immunoaffinity chromatography on anti-apoA-II and anti-apoC-III immunosorbers were affected in a selective manner.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 37 references indexed in Scilit:
- A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemiaThe American Journal of Cardiology, 1992
- A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemiaAtherosclerosis, 1991
- Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-upAtherosclerosis, 1990
- Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The finnish multicenter studyThe American Journal of Cardiology, 1988
- Apolipoproteins B, C-III and E in two major subpopulations of low-density lipoproteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Subpopulations of apolipoprotein A-I in human high-density lipoproteins their metabolic properties and response to drug therapyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1983
- The coronary primary prevention trial: Design and implementationJournal of Chronic Diseases, 1979
- Apoprotein content of plasma lipoproteins of the rat separated by gel chromatography or ultracentrifugationBiochemical Medicine, 1977